Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Puggioni (Milano, Italy), E. Heffler (Milano, Italy), G. Canonica (Milano, Italy), M. Latorre (Pisa, Italy), F. Blasi (Milano, Italy), P. Paggiaro (Pisa, Italy), M. Caminati (Verona, Italy), G. Senna (Verona, Italy). Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry. 4255

Member's Comments

No comment yet.

Related content which might interest you: Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK) Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Gender differences in patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Patterns of risk of death and asthma-related adverse outcomes in adult asthma patients receiving long-acting β2-agonist (LABA) therapy: results from the UK general practice research database (GPRD) Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care Year: 2009 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 What are common COPD symptoms in a real-life setting? The German DACCORD registry Source: International Congress 2014 – COPD markers Year: 2014 A national database study of the effectiveness of switching real-life asthma patients to fostair Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Characteristics of patients newly prescribed a long acting bronchodilator in the United Kingdom (UK) Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Characteristics of severe asthmatics treated with omalizumab, mepolizumab or no biotherapy. Data from the Belgian Severe Asthma Registry (BSAR). Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Impact of bronchiectasis on severe asthma: data from the “Severe Asthma Network Italy” (SANI) registry Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018